GlassScriptPhysician profile
Megan E Missaggia
NPI 1326452889
$8,947.48
in general payments reported to CMS, 2019-2025
48 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $1,114 · 2021: $2,075 · 2022: $867 · 2023: $1,434 · 2024: $1,063 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,844.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,541.16 | 2019-2025 | |
| Novo Nordisk INC | $1,151.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $665.77 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $572.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $474.04 | 2019-2021 | |
| Amgen INC. | $354.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $288.37 | 2019-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $268.83 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $265.73 | 2019-2024 | Verquvo, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $264.10 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $201.42 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $183.79 | 2019-2021 | |
| Astellas Pharma US INC | $145.08 | 2019-2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.26 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $129.79 | 2023-2025 | Auvelity |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Missaggia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.